Clearmind Medicine Inc. - Common Shares (CMND)

SciSparc Ltd (NASDAQ:SPRC) shares are ripping higher Monday after the company announced that its collaboration with Clearmind Medicine Inc (NASDAQ:CMND) led to a patent application for psychedelic therapy targeting cocaine addiction.

SciSparc teams up with Clearmind Medicine on innovative therapies for binge behaviors and secures FDA approval for a Tourette Syndrome Phase 2b trial.

Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol use disorder.

Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy.

Clearmind Medicine just reported results for the second quarter of 2024.

Clearmind Medicine secures a U.S. patent for its MEAI-based binge behavior treatment, marking a significant advancement in addressing Alcohol Use Disorder.

We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns!

SciSparc stock is up on Tuesday as SPRC investors learn of the company filing a new patent covering its weight loss treatment.

Clearmind Medicine shares are trading higher Friday after the company announced advancement in its proprietary MEAI-based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office.

I set daily profit goals and max loss limits to manage my risk. My daily goal is $5,000, and I cap my daily loss at the same amount.

Clearmind said its alcohol substitute was granted patents in the U.S., India and Europe. The company also highlighted that the no/low alcohol category is forecasted to grow at a volume CAGR of more than 6% between 2023 and 2027.

Clearmind Medicine shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development.

Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results.